OTCPK:MRNT.Y

Stock Analysis Report

Executive Summary

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Risks

  • Medicrea International is not covered by any analysts.

Similar Companies

Share Price & News

How has Medicrea International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:MRNT.Y

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

n/a

OTCPK:MRNT.Y

8.7%

US Medical Equipment

1.7%

US Market

No trading data on MRNT.Y.

No trading data on MRNT.Y.


Share holder returns

MRNT.YIndustryMarket
7 Day0%-1.2%1.2%
30 Day0%1.4%4.9%
90 Day5.7%4.8%3.7%
1 Yearn/a9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Medicrea International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medicrea International undervalued based on future cash flows and its price relative to the stock market?

2.31x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Medicrea International to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Medicrea International to establish if it is available at substantial discount.


Price Based on Earnings

Medicrea International is loss making, we can't compare its value to the US Medical Equipment industry average.

Medicrea International is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Medicrea International, we can't assess if its growth is good value.


Price Based on Value of Assets

Medicrea International is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Medicrea International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicrea International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MRNT.Y’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medicrea International's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Medicrea International performed over the past 5 years?

-59.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Medicrea International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Medicrea International's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Medicrea International's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Medicrea International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Medicrea International has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Medicrea International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Medicrea International's financial position?


Financial Position Analysis

Medicrea International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Medicrea International's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Medicrea International's level of debt (132.9%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (30.7% vs 132.9% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Medicrea International has less than a year of cash runway based on current free cash flow.

Medicrea International has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.2% each year.


Next Steps

Dividend

What is Medicrea International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Medicrea International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Medicrea International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Medicrea International has not reported any payouts.

Unable to verify if Medicrea International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Medicrea International has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Medicrea International's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Denys Sournac 0

0yrs

Tenure

€7,000

Compensation

Mr. Denys Sournac serves as the Owner, President and Chief Executive Officer at Orsco Laboratoire Vétérinaire, SAS. He also serves as the Chairman of Orsco Laboratoire Vétérinaire, SAS. Mr. Sournac has bee ...


CEO Compensation Analysis

Denys's remuneration is lower than average for companies of similar size in United States of America.

Denys's compensation has increased whilst company is loss making.


Management Age and Tenure

1.2yrs

Average Tenure

The average tenure for the Medicrea International management team is less than 2 years, this suggests a new team.


Board Age and Tenure

16.8yrs

Average Tenure

59yo

Average Age

The average tenure for the Medicrea International board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Fabrice Kilfiger

    Chief Financial Officer

    • Tenure: 0yrs
  • Rick Kienzle

    Chief Commercial & Business Development Officer and Director

    • Tenure: 2.3yrs
  • Denys Sournac

    Co-Founder

    • Tenure: 0yrs
    • Compensation: €7.00k
  • Jean Caffiero

    Co-Founder

    • Tenure: 16.8yrs
    • Compensation: €7.00k
  • David Ryan

    Vice President of Product Development & Marketing

    • Tenure: 0yrs
  • Nadège Bourdois

    Vice President of Human Ressources & Legal

    • Tenure: 0yrs
  • Rick Washburn

    Executive Vice President of UNiD™ ASI

    • Tenure: 1.2yrs
  • Pierre-Laurent Ravis

    Chief Information Officer

    • Tenure: 0yrs
  • Thomas Mosnier

    Chief Scientific Officer

    • Tenure: 0yrs
  • Joseph Walland

    Executive Vice President of U.S. Sales

    • Tenure: 1.2yrs

Board Members

  • M. Ory (59yo)

    Independent Director

    • Tenure: 11.5yrs
    • Compensation: €4.00k
  • Patrick Bertrand (64yo)

    Director

    • Tenure: 16.8yrs
    • Compensation: €4.00k
  • Rick Kienzle

    Chief Commercial & Business Development Officer and Director

    • Tenure: 2.3yrs
  • Denys Sournac

    Co-Founder

    • Tenure: 0yrs
    • Compensation: €7.00k
  • Marc Recton

    Independent Director

    • Tenure: 15.5yrs
    • Compensation: €4.00k
  • Christophe Bonnet

    Independent Director

    • Tenure: 16.8yrs
    • Compensation: €4.00k
  • Jean Moreno

    Independent Director

    • Tenure: 16.8yrs
    • Compensation: €4.00k
  • Jean Caffiero

    Co-Founder

    • Tenure: 16.8yrs
    • Compensation: €7.00k
  • Pierre Olivier (52yo)

    Director & CEO of Medicrea USA

    • Tenure: 0.6yrs
  • Pierre Burel

    Director

    • Tenure: 16.8yrs

Company Information

Medicrea International SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicrea International SA
  • Ticker: MRNT.Y
  • Exchange: OTCPK
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €38.914m
  • Listing Market Cap: €43.951m
  • Shares outstanding: 16.21m
  • Website: https://www.medicrea.com

Number of Employees


Location

  • Medicrea International SA
  • 5389, route de Strasbourg
  • Rillieux-la-Pape
  • Rhône-Alpes
  • 69140
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALMEDENXTPA (Euronext Paris)YesOrdinary SharesFREURJun 2006
MRNT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2006
MRNT.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDAug 2018

Biography

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; Li ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/12/16 01:23
End of Day Share Price2018/09/18 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.